Sentences with phrase «into preclinical development»

Not exact matches

The research into quantum dots containing single magnetic ions was funded with grants from the Polish National Science Centre and the Polish National Centre for Research and Development, as well as project funds from the Centre for Preclinical Research and Technology.

PsychoGenics has pioneered the translation of rodent behavioral responses into robust, high throughput, high content phenotyping and its drug discovery platforms, SmartCube ®, NeuroCube ®, and PhenoCube ® have led to shared risk partnerships with major pharma companies such as Sunovion and Roche and resulted in the discovery of several novel compounds now in clinical trials or advanced preclinical development.

These forward - looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical development of its drug candidates and advance such candidates into clinical development, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as those relating to manufacturing, the regulatory process, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward - looking statements.

In collaboration with the University of Massachusetts Medical School (UMMS) and Auburn University (AU), Lysogene is developing IND - supporting preclinical studies using AAV gene therapy technology to translate the initial proof of concept into a viable drug development program to the benefit of patients in urgent need.

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Prothena Corporation plc (NASDAQ: PRTA), announced today that they have entered into a worldwide collaboration to develop and commercialize antibodies that target alpha - synuclein, including PRX002... which is currently in preclinical development and is expected to enter Phase 1 clinical trials in patients with Parkinson's disease in 2014.

These new preclinical studies provide support for advancing the Ad26 / MVA prime - boost vaccine candidate into clinical development.